Chronic Disease Medication Adherence After Initiation of Buprenorphine for Opioid Use Disorder
Bibliographic Data
| ID | 9098519 |
|---|---|
| Authors | Hsien-Yen Chang (Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health), Hsien‐Yen Chang (0000-0002-7997-4822, Johns Hopkins University, corresponding author), Matthew Daubresse (Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health), Brendan Saloner (0000-0001-9013-3023, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, corresponding author), G Caleb Alexander (0000-0002-5622-2986, Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health) |
| Year | 2019 |
| Volume | 57 |
| Issue | 9 |
| Pages | 667-672 |
| Publication date | 2019-09-01 |
| Open Access | No |
| Type | ARTICLE |
| Venue | Medical Care (JOURNAL) |
| Journal identifiers | ISSN: 0025-7079 • E-ISSN: 1537-1948 |
| Publisher | Ovid Technologies (Wolters Kluwer Health) (PUBLISHER) |
| DOI | 10.1097/mlr.0000000000001165 |
| PMID | 31404013 |
| OpenAlex | W2968655949 |
| Language | EN |
| Citations received | 2 |
| References cited | 19 |
BACKGROUND: Although buprenorphine is an evidence-based treatment for opioid use disorder (OUD), it is unknown whether buprenorphine use may affect patients' adherence to treatments for chronic, unrelated conditions. OBJECTIVES: To quantify the effect of buprenorphine treatment on patient adherence to 5 therapeutic classes: (1) antilipids; (2) antipsychotics; (3) antiepileptics; (4) antidiabetics; and (5) antidepressants. RESEARCH DESIGN: This was a retrospective cohort study. SUBJECTS: We started with 12,719 commercially ensured individuals with a diagnosis of OUD and the buprenorphine initiation between January 2011 and June 2015 using Truven Health's MarketScan data. Individuals using any of the 5 therapeutic classes of interest were included. MEASURES: Within the 180-day period post buprenorphine initiation, we derived 2 daily indicators: having buprenorphine and having chronic medication on hand for each therapeutic class of interest. We applied logistic regression to assess the association between these 2 daily indicators, adjusting for demographics, morbidity, and baseline adherence. RESULTS: Across the 5 therapeutic classes, the probability with a given treatment on hand was always higher on days when buprenorphine was on hand. After adjustment for demographics, morbidity, and baseline adherence, buprenorphine was associated with a greater odds of adherence to antilipids [odds ratio (OR), 1.27; 95% confidence interval (CI), 1.04-1.54], antiepileptics (OR, 1.22; CI, 1.10-1.36) and antidepressants (OR, 1.42; CI, 1.32-1.60). CONCLUSIONS: Using buprenorphine to treat OUD may increase adherence to treatments for chronic unrelated conditions, a finding of particular importance given high rates of mental illness and other comorbidities among many individuals with OUD
Buprenorphine · Cohort study · Confidence interval · Logistic regression · Odds ratio · Opioid · Opioid use disorder · Psychiatry · Retrospective cohort study · HIV, Drug Use, Sexual Risk · Internal Medicine · Medicine · Opioid Use Disorder Treatment · Substance Abuse Treatment and Outcomes
Mortality risk during and after opioid substitution treatment
Adherence to Medication
Toward a behavioral economic understanding of drug dependence
Patterns of Buprenorphine-Naloxone Treatment for Opioid Use Disorder in a Multistate Population
Casemix Adjustment of Managed Care Claims Data Using the Clinical Classification for Health Policy Research Method
Interventions to Increase Self-efficacy in the Context of Addiction Behaviours
| Citations per year | 0.67 |
|---|---|
| Citation span | 2023 - 2025 (3) |
| Highly cited | No |